189
Participants
Start Date
May 28, 2012
Primary Completion Date
March 9, 2023
Study Completion Date
March 9, 2023
LGX818
MEK162
LEE011
Melanoma Institute Australia, North Sydney
Melanoma Institute Australia, North Sydney
Westmead Hospital-Redbank Rd, Westmead
Westmead Hospital, Westmead
Westmead Hospital-Redbank Rd, Northmead
UZ Leuven- Gasthuisberg Campus, Leuven
University Hospital Zürich, Dermatology, Zurich-Airport
Kantonsspital St. Gallen, Sankt Gallen
ASST Grande Ospedale Metropolitano Niguarda - Presidio Ospedaliero Ospedale Niguarda Ca' Granda, Milan
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore
Hospital Universitario HM Sanchinarro ? CIOCC, Madrid
H. Lee Moffitt Cancer Center & Research Institute, Inc., Tampa
Moffitt McKinley Outpatient Center, Tampa
Hôpital Saint louis, Paris
Service de radiologie - Hopital Saint Louis, Paris
The University of Texas MD Anderson Cancer Center, Houston
IRCCS Fondazione Pascale, Naples
Azienda Ospedaliera Monaldi, Napoli
Azienda Ospedaliera Universitaria Federico II, Napoli
Istituto Nazionale per lo studio e la cura dei tumori Fondazione Giovanni Pascale, Napoli
National Cancer Centre Singapore, Singapore
Massachusetts General Hospital, Boston
Ophthalmic Consultants of Boston Inc (OCB), Boston
Chris O'Brien Lifehouse Hospital, Camperdown
Sir Mortimer B. Davis-Jewish General Hospital, Montreal
Hospital Universitario Vall d'Hebrón - PPDS, Barcelona
Lead Sponsor
Pfizer
INDUSTRY